PMC:7105881 / 52987-53772 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1653","span":{"begin":0,"end":8},"obj":"Species"},{"id":"1659","span":{"begin":254,"end":262},"obj":"Species"},{"id":"1660","span":{"begin":322,"end":330},"obj":"Species"},{"id":"1661","span":{"begin":462,"end":476},"obj":"Species"},{"id":"1662","span":{"begin":683,"end":691},"obj":"Species"},{"id":"1663","span":{"begin":487,"end":502},"obj":"Disease"}],"attributes":[{"id":"A1653","pred":"tao:has_database_id","subj":"1653","obj":"Tax:1335626"},{"id":"A1659","pred":"tao:has_database_id","subj":"1659","obj":"Tax:1335626"},{"id":"A1660","pred":"tao:has_database_id","subj":"1660","obj":"Tax:1335626"},{"id":"A1661","pred":"tao:has_database_id","subj":"1661","obj":"Tax:10245"},{"id":"A1662","pred":"tao:has_database_id","subj":"1662","obj":"Tax:1335626"},{"id":"A1663","pred":"tao:has_database_id","subj":"1663","obj":"MESH:D014615"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T303","span":{"begin":52,"end":60},"obj":"Body_part"},{"id":"T304","span":{"begin":138,"end":146},"obj":"Body_part"},{"id":"T305","span":{"begin":240,"end":247},"obj":"Body_part"},{"id":"T306","span":{"begin":396,"end":403},"obj":"Body_part"},{"id":"T307","span":{"begin":642,"end":650},"obj":"Body_part"},{"id":"T308","span":{"begin":694,"end":701},"obj":"Body_part"}],"attributes":[{"id":"A303","pred":"fma_id","subj":"T303","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A304","pred":"fma_id","subj":"T304","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A305","pred":"fma_id","subj":"T305","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A306","pred":"fma_id","subj":"T306","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A307","pred":"fma_id","subj":"T307","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A308","pred":"fma_id","subj":"T308","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T264","span":{"begin":68,"end":72},"obj":"Disease"},{"id":"T265","span":{"begin":462,"end":470},"obj":"Disease"},{"id":"T266","span":{"begin":487,"end":495},"obj":"Disease"},{"id":"T267","span":{"begin":504,"end":507},"obj":"Disease"}],"attributes":[{"id":"A264","pred":"mondo_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A265","pred":"mondo_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/MONDO_0002595"},{"id":"A266","pred":"mondo_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/MONDO_0002595"},{"id":"A267","pred":"mondo_id","subj":"T267","obj":"http://purl.obolibrary.org/obo/MONDO_0012481"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T638","span":{"begin":333,"end":341},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T639","span":{"begin":471,"end":476},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T640","span":{"begin":523,"end":527},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"},{"id":"T641","span":{"begin":554,"end":555},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T59623","span":{"begin":138,"end":146},"obj":"Chemical"},{"id":"T5808","span":{"begin":240,"end":247},"obj":"Chemical"},{"id":"T41976","span":{"begin":333,"end":341},"obj":"Chemical"},{"id":"T56868","span":{"begin":396,"end":403},"obj":"Chemical"},{"id":"T9220","span":{"begin":504,"end":507},"obj":"Chemical"},{"id":"T74554","span":{"begin":642,"end":650},"obj":"Chemical"},{"id":"T62636","span":{"begin":694,"end":701},"obj":"Chemical"}],"attributes":[{"id":"A60107","pred":"chebi_id","subj":"T59623","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A67330","pred":"chebi_id","subj":"T5808","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A87588","pred":"chebi_id","subj":"T41976","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A15302","pred":"chebi_id","subj":"T56868","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A61194","pred":"chebi_id","subj":"T9220","obj":"http://purl.obolibrary.org/obo/CHEBI_25351"},{"id":"A73138","pred":"chebi_id","subj":"T74554","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A23488","pred":"chebi_id","subj":"T62636","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}

{"project":"2_test","denotations":[{"id":"32265848-30558354-36511226","span":{"begin":523,"end":527},"obj":"30558354"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}

{"project":"LitCovid-sentences","denotations":[{"id":"T287","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"T288","span":{"begin":61,"end":263},"obj":"Sentence"},{"id":"T289","span":{"begin":264,"end":529},"obj":"Sentence"},{"id":"T290","span":{"begin":530,"end":785},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T860","span":{"begin":0,"end":8},"obj":"SP_9"},{"id":"T861","span":{"begin":68,"end":72},"obj":"SP_10"},{"id":"T862","span":{"begin":124,"end":129},"obj":"NCBITaxon:10239"},{"id":"T863","span":{"begin":254,"end":262},"obj":"SP_9"},{"id":"T864","span":{"begin":308,"end":318},"obj":"GO:0042571"},{"id":"T865","span":{"begin":322,"end":330},"obj":"SP_9"},{"id":"T866","span":{"begin":394,"end":403},"obj":"PG_4"},{"id":"T867","span":{"begin":449,"end":454},"obj":"NCBITaxon:10239"},{"id":"T868","span":{"begin":455,"end":461},"obj":"SO:0000440"},{"id":"T869","span":{"begin":462,"end":470},"obj":"NCBITaxon:7742"},{"id":"T870","span":{"begin":471,"end":476},"obj":"NCBITaxon:10239"},{"id":"T871","span":{"begin":487,"end":495},"obj":"NCBITaxon:7742"},{"id":"T872","span":{"begin":580,"end":594},"obj":"BV_15"},{"id":"T873","span":{"begin":683,"end":691},"obj":"SP_9"},{"id":"T874","span":{"begin":692,"end":701},"obj":"PG_1"},{"id":"T875","span":{"begin":743,"end":747},"obj":"SP_9"},{"id":"T88188","span":{"begin":0,"end":8},"obj":"SP_9"},{"id":"T13819","span":{"begin":68,"end":72},"obj":"SP_10"},{"id":"T72806","span":{"begin":124,"end":129},"obj":"NCBITaxon:10239"},{"id":"T97891","span":{"begin":254,"end":262},"obj":"SP_9"},{"id":"T51565","span":{"begin":308,"end":318},"obj":"GO:0042571"},{"id":"T29534","span":{"begin":322,"end":330},"obj":"SP_9"},{"id":"T79419","span":{"begin":394,"end":403},"obj":"PG_4"},{"id":"T48585","span":{"begin":449,"end":454},"obj":"NCBITaxon:10239"},{"id":"T75113","span":{"begin":455,"end":461},"obj":"SO:0000440"},{"id":"T62016","span":{"begin":462,"end":470},"obj":"NCBITaxon:7742"},{"id":"T3440","span":{"begin":471,"end":476},"obj":"NCBITaxon:10239"},{"id":"T94849","span":{"begin":487,"end":495},"obj":"NCBITaxon:7742"},{"id":"T8643","span":{"begin":580,"end":594},"obj":"BV_15"},{"id":"T62008","span":{"begin":683,"end":691},"obj":"SP_9"},{"id":"T23980","span":{"begin":692,"end":701},"obj":"PG_1"},{"id":"T68563","span":{"begin":743,"end":747},"obj":"SP_9"}],"text":"MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins\nUnlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines."}